Drug application
CIMERLI (RANIBIZUMAB-EQRN)
Drugs@FDA BLA 761165 · SANDOZ INC
Key facts
| Drug name | CIMERLI |
|---|---|
| Active ingredients | RANIBIZUMAB-EQRN |
| Application type | BLA |
| Application number | 761165 |
| Company | SANDOZ INC |
| Dosage forms | INJECTABLE, INJECTION |
| Strength | 0.3MG(6MG/ML) |
| Marketing status | Prescription |
| Reference listed drug | No |
| Latest submission status date | Aug 2, 2022 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: